Roche Withdraws Tecentric for Bladder Cancer Indication

As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody Tecentriq (atezolizumab) for a specific type of previously-untreated metastatic bladder cancer.